# Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression

> **NCT03756129** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 70 (actual)

## Conditions studied

- Depressive Disorder, Treatment-Resistant

## Interventions

- **DRUG:** MIJ821
- **DRUG:** Placebo
- **DRUG:** Ketamine

## Key facts

- **NCT ID:** NCT03756129
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-08
- **Primary completion:** 2020-03-23
- **Final completion:** 2020-03-23
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2021-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03756129

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03756129, "Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03756129. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*